{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:59:33Z","timestamp":1760403573448,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.euroneuro.2021.09.008","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T10:38:25Z","timestamp":1634294305000},"page":"1-3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prion diseases"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7750-896X","authenticated-orcid":false,"given":"Raquel","family":"S\u00e1nchez-Valle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.euroneuro.2021.09.008_bib0001","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1056\/NEJMc2000687","article-title":"Variant Creutzfeldt-Jakob disease diagnosed 7.5 years after occupational exposure","volume":"383","author":"Brandel","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.euroneuro.2021.09.008_bib0002","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1212\/WNL.55.8.1075","article-title":"Iatrogenic Creutzfeldt-Jakob disease at the millennium","volume":"55","author":"Brown","year":"2000","journal-title":"Neurology"},{"issue":"9006","key":"10.1016\/j.euroneuro.2021.09.008_bib0003","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0140-6736(96)91407-5","article-title":"A new variant of prion disease","volume":"347","author":"Collinge","year":"1996","journal-title":"Lancet"},{"issue":"9528","key":"10.1016\/j.euroneuro.2021.09.008_bib0004","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1016\/S0140-6736(06)68930-7","article-title":"Kuru in the 21st century\u2013an acquired human prion disease with very long incubation periods","volume":"367","author":"Collinge","year":"2006","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.euroneuro.2021.09.008_bib0005","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1474-4422(20)30477-4","article-title":"Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease","volume":"20","author":"Hermann","year":"2021","journal-title":"Lancet Neurol."},{"issue":"10","key":"10.1016\/j.euroneuro.2021.09.008_bib0006","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1474-4422(20)30238-6","article-title":"Potential human transmission of amyloid \u03b2 pathology: surveillance and risks","volume":"19","author":"Lauwers","year":"2020","journal-title":"Lancet Neurol."},{"issue":"322","key":"10.1016\/j.euroneuro.2021.09.008_bib0007","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad5169","article-title":"Quantifying prion disease penetrance using large population control cohorts","volume":"20","author":"Minikel","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"19","key":"10.1016\/j.euroneuro.2021.09.008_bib0008","doi-asserted-by":"crossref","first-page":"10615","DOI":"10.1093\/nar\/gkaa616","article-title":"Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints","volume":"48","author":"Minikel","year":"2020","journal-title":"Nucleic Acids Res."},{"issue":"23","key":"10.1016\/j.euroneuro.2021.09.008_bib0009","doi-asserted-by":"crossref","first-page":"13363","DOI":"10.1073\/pnas.95.23.13363","volume":"95","author":"Prusiner","year":"1998","journal-title":"Prions. Proc. Natl. Acad. Sci. U. S. A."},{"issue":"4","key":"10.1016\/j.euroneuro.2021.09.008_bib0010","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1176\/jnp.17.4.489","article-title":"Psychiatric manifestations of Creutzfeldt-Jakob disease: a 25-year analysis","volume":"17","author":"Wall","year":"2005","journal-title":"J. Neuropsychiatry Clin. Neurosci."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X21007604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X21007604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:59:55Z","timestamp":1760378395000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X21007604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":10,"alternative-id":["S0924977X21007604"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2021.09.008","relation":{},"ISSN":["0924-977X"],"issn-type":[{"type":"print","value":"0924-977X"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prion diseases","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2021.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}